{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:08:10Z","timestamp":1789992490743,"version":"4.0.1"},"reference-count":63,"publisher":"American Chemical Society (ACS)","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["Grant Number IIRP-23\/4760"],"award-info":[{"award-number":["Grant Number IIRP-23\/4760"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recently, explorations are being undertaken involving chemo-immunotherapy based on targeting cancer cells and tumor-associated macrophages (TAMs). However, these strategies mainly focus on delivering TAM modulators and chemotherapy simultaneously, without considering the effect of chemotherapy on TAMs and which may compromise TAM-modulatory action. This necessitates investigations involving sequential treatment wherein pretreatment would enable efficient M2-to-M1 repolarization before administration of chemotherapy. In this study, mannose-targeted liposomes encapsulating resiquimod (M-LIPO-RES) and doxorubicin (M-LIPO-DOX) were developed to target M2-type TAMs and cancer cells, respectively. The formulations (M-LIPO-RES and M-LIPO-DOX) were characterized for particle size, zeta potential, surface chemistry, morphology, drug entrapment efficiency, release profile, and hemolysis potential. The results showed that mannose-targeted liposomes possess a marked increase in cellular uptake in M2-polarized macrophages and MDA-MB-231 cells, revealing their potential for receptor-mediated cellular internalization. M-LIPO-RES-mediated macrophage polarization from the M2 to M1 phenotype was confirmed by analysis of the cytokine profile and estimation of TAM-associated surface proteins (e.g., CD206 and CD86), both in vitro and in vivo. The biodistribution study indicated the preferential accumulation of the developed formulation at the tumor site following intravenous administration. Furthermore, the anticancer effect was studied in the immunocompetent 4T1 mouse model, which indicated improved anticancer effect after sequential treatment (M-LIPO-RES followed by M-LIPO-DOX). Additionally, cardiac markers (i.e., troponin and CK-MB) were decreased in the targeted formulation group as compared to other treated groups, indicating a favorable cardiac safety profile. The presented targeted nano strategy preserves the immune-modulatory effect and reveals great potential for immuno-chemo response in triple-negative breast cancer (TNBC) therapy.<\/jats:p>","DOI":"10.1021\/acsabm.6c00834","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:01:57Z","timestamp":1789030917000},"page":"8518-8539","source":"Crossref","is-referenced-by-count":0,"title":["Sequential Mannose-Targeted Nanotherapy Orchestrates Tumor-Associated Macrophage Repolarization and Chemotherapeutic Response in Triple-Negative Breast Cancer"],"prefix":"10.1021","volume":"9","author":[{"given":"Nagma","family":"Banjare","sequence":"first","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]},{"name":"Academy of Scientific and Innovative Research (AcSIR) , ,","place":["Ghaziabad, India, 201002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Singh","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]},{"name":"Academy of Scientific and Innovative Research (AcSIR) , ,","place":["Ghaziabad, India, 201002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamalpreet Kaur","family":"Sandha","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]},{"name":"University of Miami , , , ,","place":["Miami, Florida, United States, 33136"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajeet","family":"Singh","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]},{"name":"Academy of Scientific and Innovative Research (AcSIR) , ,","place":["Ghaziabad, India, 201002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhradeep","family":"Kuiry","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saika","family":"Saman","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]},{"name":"Academy of Scientific and Innovative Research (AcSIR) , ,","place":["Ghaziabad, India, 201002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagaraju","family":"Nekkala","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshank K","family":"Singh","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]},{"name":"Academy of Scientific and Innovative Research (AcSIR) , ,","place":["Ghaziabad, India, 201002"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-7000","authenticated-orcid":true,"given":"Prem N.","family":"Gupta","sequence":"additional","affiliation":[{"name":"CSIR-Indian Institute of Integrative Medicine , , Canal Road , ,","place":["Jammu, India, 180001"]},{"name":"Academy of Scientific and Innovative Research (AcSIR) , ,","place":["Ghaziabad, India, 201002"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"2026092100091054800_cit1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920986749","article-title":"Update on systemic treatment in early triple negative breast cancer","volume":"13","author":"Nunez Abad","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"key":"2026092100091054800_cit2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/BCTT.S85442","article-title":"Triple negative breast cancer: an Indian perspective","volume":"7","author":"Akhtar","year":"2015","journal-title":"Breast Cancer: Targets Ther."},{"issue":"9","key":"2026092100091054800_cit3","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3978\/j.issn.2072-1439.2014.08.13","article-title":"The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markers","volume":"6","author":"Jiao","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"2026092100091054800_cit4","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.tips.2015.08.009","article-title":"Targeted therapies for triple negative breast cancer: combating a stubborn disease","volume":"36","author":"Kalimutho","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"2026092100091054800_cit5","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1543636","article-title":"Metabolomic profiling and biomarker identification for early detection and therapeutic targeting of doxorubicin-induced cardiotoxicity","volume":"13","author":"Ding","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"issue":"7","key":"2026092100091054800_cit6","doi-asserted-by":"publisher","first-page":"7682","DOI":"10.1021\/acsnano.0c03648","article-title":"Complement activation: A potential threat to the safety of poly(ethylene glycol)-coated nanomedicines","volume":"14","author":"Gabizon","year":"2020","journal-title":"ACS Nano"},{"issue":"7","key":"2026092100091054800_cit7","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/02841869409083948","article-title":"Clinical studies of liposome-encapsulated doxorubicin","volume":"33","author":"Gabizon","year":"1994","journal-title":"Acta Oncol."},{"issue":"12","key":"2026092100091054800_cit8","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.addr.2011.06.017","article-title":"Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: Prediction and prevention","volume":"63","author":"Szebeni","year":"2011","journal-title":"Adv. Drug Delivery Rev."},{"issue":"8","key":"2026092100091054800_cit9","doi-asserted-by":"publisher","first-page":"586","DOI":"10.2174\/1570163817666200518081955","article-title":"Targeting different pathways using novel combination therapy in triple negative breast cancer","volume":"20","author":"Mir","year":"2020","journal-title":"Curr. Cancer Drug Targets"},{"issue":"1","key":"2026092100091054800_cit10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s42003-023-04525-7","article-title":"Tissue-resident macrophages are major tumor-associated macrophage resources, contributing to early TNBC development, recurrence, and metastases","volume":"6","author":"Hirano","year":"2023","journal-title":"Commun. Biol."},{"key":"2026092100091054800_cit11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2015.10.009","article-title":"Immune suppressive mechanisms in the tumor microenvironment","volume":"39","author":"Munn","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"2026092100091054800_cit12","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3389\/fimmu.2020.00940","article-title":"The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses","volume":"11","author":"Labani-Motlagh","year":"2020","journal-title":"Front. Immunol."},{"key":"2026092100091054800_cit13","doi-asserted-by":"publisher","first-page":"5879","DOI":"10.2147\/IJN.S123437","article-title":"Nanomedicine applications in the treatment of breast cancer: current state of the art","volume":"12","author":"Wu","year":"2017","journal-title":"Int. J. Nanomed."},{"issue":"9","key":"2026092100091054800_cit14","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/cancers17091509","article-title":"Magrolimab therapy in conjunction with conventional chemotherapeutics slows disease progression in pediatric acute myeloid leukemia patient-derived xenograft models","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers"},{"issue":"5","key":"2026092100091054800_cit15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1126037","article-title":"Motolimod effectively drives immune activation in advanced cancer patients","volume":"5","author":"Dietsch","year":"2016","journal-title":"Oncoimmunology"},{"issue":"8","key":"2026092100091054800_cit16","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"2026092100091054800_cit17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112667","article-title":"New drug approvals for 2019: synthesis and clinical applications","volume":"205","author":"Yuan","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"2026092100091054800_cit18","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s40268-020-00314-3","article-title":"Pexidartinib (TURALIO\u2122): the first FDA-indicated systemic treatment for tenosynovial giant cell tumor","volume":"20","author":"Monestime","year":"2020","journal-title":"Drugs R&D"},{"issue":"1","key":"2026092100091054800_cit19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"key":"2026092100091054800_cit20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1723270","article-title":"CAR-M therapy in the era of tumor immunotherapy: current research progress and engineering strategies","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"2026092100091054800_cit21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"22","key":"2026092100091054800_cit22","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.7150\/thno.34429","article-title":"Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles","volume":"9","author":"Da Silva","year":"2019","journal-title":"Theranostics"},{"key":"2026092100091054800_cit23","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.actbio.2020.09.038","article-title":"Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy","volume":"133","author":"Figueiredo","year":"2021","journal-title":"Acta Biomater."},{"issue":"24","key":"2026092100091054800_cit24","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202211332","article-title":"Reprogramming hypoxic tumor-associated macrophages by nanoglycoclusters for boosted cancer immunotherapy","volume":"35","author":"Zhao","year":"2023","journal-title":"Adv. Mater."},{"issue":"42","key":"2026092100091054800_cit25","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201903242","article-title":"A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy","volume":"31","author":"Phuengkham","year":"2019","journal-title":"Adv. Mater."},{"key":"2026092100091054800_cit26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jconrel.2019.09.021","article-title":"Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy","volume":"313","author":"Wei","year":"2019","journal-title":"J. Controlled Release"},{"key":"2026092100091054800_cit27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103551","article-title":"Mannose-modified co-loaded zoledronic liposomes deplete M2 tumor-associated macrophages to enhance anti-tumor effect of doxorubicin on TNBC","volume":"74","author":"Wendong","year":"2022","journal-title":"J. Drug Delivery Sci. Technol."},{"issue":"14","key":"2026092100091054800_cit28","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202208059","article-title":"X-ray-guided in situ genetic engineering of macrophages for sustained cancer immunotherapy","volume":"35","author":"Zhao","year":"2023","journal-title":"Adv. Mater."},{"issue":"14","key":"2026092100091054800_cit29","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201701398","article-title":"Mannose and mannose-6-phosphate receptor\u2212targeted drug delivery systems and their application in cancer therapy","volume":"7","author":"Dalle Vedove","year":"2018","journal-title":"Adv. Healthcare Mater."},{"issue":"1","key":"2026092100091054800_cit30","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2023.2283898","article-title":"Detoxified pneumolysin derivative \u0394A146Ply inhibits triple-negative breast cancer metastasis mainly via mannose receptor-mediated autophagy inhibition","volume":"15","author":"Zhang","year":"2024","journal-title":"Virulence"},{"issue":"2","key":"2026092100091054800_cit31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1208\/s12249-012-9788-1","article-title":"Development of mannosylated liposomes using synthesized N-octadecyl-D-mannopyranosylamine to enhance gastrointestinal permeability for protein delivery","volume":"13","author":"Witoonsaridsilp","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"2026092100091054800_cit32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jconrel.2016.01.039","article-title":"Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity","volume":"225","author":"Patil","year":"2016","journal-title":"J. Controlled Release"},{"issue":"9","key":"2026092100091054800_cit33","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1080\/1061186X.2016.1191081","article-title":"Coencapsulation of alendronate and doxorubicin in pegylated liposomes: A novel formulation for chemoimmunotherapy of cancer","volume":"24","author":"Shmeeda","year":"2016","journal-title":"J. Drug Target."},{"issue":"10","key":"2026092100091054800_cit34","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13101696","article-title":"Liposomal resiquimod for enhanced immunotherapy of peritoneal metastases of colorectal cancer","volume":"13","author":"Pauli","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026092100091054800_cit35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418422","article-title":"Fluvoxamine maleate alleviates amyloid-beta load and neuroinflammation in 5XFAD mice to ameliorate Alzheimer\u2019s disease pathology","volume":"15","author":"Kaur","year":"2024","journal-title":"Front. Immunol."},{"key":"2026092100091054800_cit36","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.jconrel.2024.12.078","article-title":"Autophagy inhibition alleviates tumor desmoplasia and improves the efficacy of locally and systemically administered liposomal doxorubicin","volume":"378","author":"Sandha","year":"2025","journal-title":"J. Controlled Release"},{"issue":"8","key":"2026092100091054800_cit37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41551-018-0236-8","article-title":"TLR7\/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy","volume":"2","author":"Rodell","year":"2018","journal-title":"Nat. Biomed. Eng."},{"issue":"12","key":"2026092100091054800_cit38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0144630","article-title":"Histochemical detection of collagen fibers by sirius red\/fast green is more sensitive than van Gieson or sirius red alone in normal and inflamed rat colon","volume":"10","author":"Segnani","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"2026092100091054800_cit39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3892\/ijo.2022.5371","article-title":"The TLR7\/8 agonist R848 optimizes host and tumor immunity to improve therapeutic efficacy in murine lung cancer","volume":"61","author":"Zhou","year":"2022","journal-title":"Int. J. Oncol."},{"issue":"2","key":"2026092100091054800_cit40","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae\u2014The first FDA-approved nano-drug: Lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J. Controlled Release"},{"issue":"2","key":"2026092100091054800_cit41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1208\/s12248-026-01222-1","article-title":"Development of an in vitro release test to characterize Onivyde using Bio-Beads SM-2 resin","volume":"28","author":"Juang","year":"2026","journal-title":"AAPS J."},{"issue":"3","key":"2026092100091054800_cit42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0168-3659(02)00294-8","article-title":"Development of an in vitro drug release assay that accurately predicts in vivo drug retention for liposome-based delivery systems","volume":"84","author":"Shabbits","year":"2002","journal-title":"J. Controlled Release"},{"key":"2026092100091054800_cit43","doi-asserted-by":"publisher","DOI":"10.1016\/j.nxnano.2025.100209","article-title":"Liposomes for drug delivery: classification, therapeutic applications, and limitations","volume":"8","author":"Chelliah","year":"2025","journal-title":"Next Nanotechnol."},{"issue":"7","key":"2026092100091054800_cit44","doi-asserted-by":"publisher","first-page":"885","DOI":"10.3390\/pharmaceutics17070885","article-title":"Advances in liposomal drug delivery: multidirectional perspectives on overcoming biological barriers","volume":"17","author":"Sobol","year":"2025","journal-title":"Pharmaceutics"},{"key":"2026092100091054800_cit45","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2022.114624","article-title":"Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy","volume":"192","author":"Sun","year":"2023","journal-title":"Adv. Drug Delivery Rev."},{"issue":"1","key":"2026092100091054800_cit46","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1038\/s41467-023-41438-9","article-title":"Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"issue":"19","key":"2026092100091054800_cit47","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.3390\/cancers14194829","article-title":"Association of CD206 protein expression with immune infiltration and prognosis in patients with triple-negative breast cancer","volume":"14","author":"Bobrie","year":"2022","journal-title":"Cancers"},{"issue":"6","key":"2026092100091054800_cit48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/aps.2017.10","article-title":"Codelivery of dihydroartemisinin and doxorubicin in mannosylated liposomes for drug-resistant colon cancer therapy","volume":"38","author":"Kang","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"issue":"43","key":"2026092100091054800_cit49","doi-asserted-by":"publisher","first-page":"15216","DOI":"10.1002\/chem.201603294","article-title":"Tumor-targeted drug delivery with mannose-functionalized nanoparticles self-assembled from amphiphilic \u03b2-cyclodextrins","volume":"22","author":"Ye","year":"2016","journal-title":"Chem. \u2212 Eur. J."},{"key":"2026092100091054800_cit50","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115550","article-title":"Beyond the EPR effect: intravital microscopy analysis of nanoparticle drug delivery to tumors","volume":"219","author":"Belyaev","year":"2025","journal-title":"Adv. Drug Delivery Rev."},{"issue":"1","key":"2026092100091054800_cit51","doi-asserted-by":"publisher","DOI":"10.13188\/2325-4653.1000003","article-title":"Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics","volume":"1","author":"Azad","year":"2014","journal-title":"J. Cytol. Mol. Biol."},{"issue":"12","key":"2026092100091054800_cit52","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113564","article-title":"Heterogeneity and transcriptional drivers of triple-negative breast cancer","volume":"42","author":"Jovanovi\u0107","year":"2023","journal-title":"Cell Rep."},{"issue":"10","key":"2026092100091054800_cit53","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1021\/acs.nanolett.1c00209","article-title":"Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli combined with immunogenic cell death for cancer immunotherapy","volume":"21","author":"Wei","year":"2021","journal-title":"Nano Lett."},{"key":"2026092100091054800_cit54","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jconrel.2024.06.041","article-title":"Resiquimod-loaded cationic liposomes cure mice with peritoneal carcinomatosis and induce specific anti-tumor immunity","volume":"372","author":"Chao","year":"2024","journal-title":"J. Controlled Release"},{"key":"2026092100091054800_cit55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1302751","article-title":"Effects of immunogenic cell death-inducing chemotherapeutics on the immune cell activation and tertiary lymphoid structure formation in melanoma","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"2026092100091054800_cit56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"2026092100091054800_cit57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1677363","article-title":"Roles of tumor-associated macrophages in triple-negative breast cancer progression","volume":"16","author":"Wu","year":"2025","journal-title":"Front. Immunol."},{"issue":"8","key":"2026092100091054800_cit58","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat. Immunol."},{"issue":"5","key":"2026092100091054800_cit59","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/cvr\/cvz192","article-title":"Liposomal doxorubicin attenuates cardiotoxicity via induction of interferon-related DNA damage resistance","volume":"116","author":"Gy\u00f6ngy\u00f6si","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"2","key":"2026092100091054800_cit60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.5625\/lar.2017.33.2.165","article-title":"Comparision of doxorubicin-induced cardiotoxicity in the ICR mice of different sources","volume":"33","author":"Kim","year":"2017","journal-title":"Lab. Anim. Res."},{"key":"2026092100091054800_cit61","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3389\/fvets.2020.00320","article-title":"Canine traditional laboratory tests and cardiac biomarkers","volume":"7","author":"Gavazza","year":"2020","journal-title":"Front. Vet. Sci."},{"issue":"1","key":"2026092100091054800_cit62","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12885-025-13583-5","article-title":"Serum cardiac and inflammatory biomarker levels following chemotherapy among female patients with breast cancer attending at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia","volume":"25","author":"Getie","year":"2025","journal-title":"BMC Cancer"},{"key":"2026092100091054800_cit63","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jconrel.2020.11.013","article-title":"Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy","volume":"330","author":"Zhang","year":"2021","journal-title":"J. Controlled Release"}],"container-title":["ACS Applied Bio Materials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsabm.6c00834","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aabmcb\/article-pdf\/9\/18\/8518\/68467992\/mt-2026-008345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aabmcb\/article-pdf\/9\/18\/8518\/68467992\/mt-2026-008345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T11:15:36Z","timestamp":1789989336000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aabmcb\/article\/9\/18\/8518\/5427487\/Sequential-Mannose-Targeted-Nanotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":63,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9,10]]},"published-print":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acsabm.6c00834","relation":{},"ISSN":["2576-6422"],"issn-type":[{"value":"2576-6422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}